NCT00818519View on ClinicalTrials.gov

GA YAZ ACNE in China Phase III

PHASE3CompletedINTERVENTIONAL

Enrollment

179

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Acne Vulgaris

Interventions

DRUG

EE20/Drospirenone (YAZ, BAY86-5300)

20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd

DRUG

Placebo

Inert tablet

Trial Locations (7)

100032

Beijing

100853

Beijing

200043

Shanghai

210042

Nanjing

410011

Changsha

510630

Guangzhou

610041

Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY